Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the efficacy and safety of regorafenib plus sintilimab
compared with regorafenib alone as the second-line treatment for patients with unresectable
hepatocellullar carcinoma (HCC).
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center Cancer Hospital of Guangxi Medical University Chinese Academy of Medical Sciences Fifth Affiliated Hospital, Sun Yat-Sen University Jiangmen Central Hospital Jieyang People's Hospital Peking University Shenzhen Hospital Second Affiliated Hospital of Nanchang University Shantou Central Hospital Shenzhen People's Hospital The First People's Hospital of Zhaoqing Third Affiliated Hospital, Sun Yat-Sen University Yuebei People's Hospital Zhaoqing Gaoyao People's Hospital ZhuHai Hospital